

Table S4. Number and percentage of adults under active treatment for obstructive airway diseases reporting unsolicited adverse events within 31 days post-vaccination (total vaccinated cohort)

Event by MedDRA primary system organ class and preferred term	OAD-treated adults (meta-analysis)	
	N=222	
	n	% (95% CI)
At least 1 symptom	67	30.2 (24.2; 36.7)
Blood and lymphatic system disorders		
Lymph node pain	1	0.5 (0.0; 2.5)
Lymphadenitis	1	0.5 (0.0; 2.5)
Cardiac disorders		
Cardiac failure congestive	1	0.5 (0.0; 2.5)
Diastolic dysfunction	1	0.5 (0.0; 2.5)
Left ventricular hypertrophy	1	0.5 (0.0; 2.5)
Ear and labyrinth disorders		
Deafness	1	0.5 (0.0; 2.5)
Eye disorders		
Eye irritation	1	0.5 (0.0; 2.5)
Gastrointestinal disorders		
Abdominal pain	1	0.5 (0.0; 2.5)
Diarrhea	1	0.5 (0.0; 2.5)
Dyspepsia	1	0.5 (0.0; 2.5)
Gastroesophageal reflux disease	1	0.5 (0.0; 2.5)
Nausea	1	0.5 (0.0; 2.5)
General disorders and administration site conditions		
Chills	1	0.5 (0.0; 2.5)
Crying	1	0.5 (0.0; 2.5)
Fatigue	2	0.9 (0.1; 3.2)
Injection site bruising	1	0.5 (0.0; 2.5)

Injection site discomfort	1	0.5 (0.0; 2.5)
Injection site induration	1	0.5 (0.0; 2.5)
Injection site pain	1	0.5 (0.0; 2.5)
Injection site paresthesia	1	0.5 (0.0; 2.5)
Injection site pruritus	4	1.8 (0.5; 4.5)
Injection site reaction	1	0.5 (0.0; 2.5)
Mass	1	0.5 (0.0; 2.5)
Pain	2	0.9 (0.1; 3.2)
Infections and infestations		
Bacterial vaginosis	1	0.5 (0.0; 2.5)
Bronchitis	4	1.8 (0.5; 4.5)
Conjunctivitis bacterial	1	0.5 (0.0; 2.5)
Diverticulitis	1	0.5 (0.0; 2.5)
Enterococcal sepsis	1	0.5 (0.0; 2.5)
Fungal infection	1	0.5 (0.0; 2.5)
Gastroenteritis	2	0.9 (0.1; 3.2)
Gastroenteritis viral	2	0.9 (0.1; 3.2)
Infection	1	0.5 (0.0; 2.5)
Influenza	1	0.5 (0.0; 2.5)
Laryngitis	1	0.5 (0.0; 2.5)
Nasopharyngitis	7	3.2 (1.3; 6.4)
Pharyngitis	1	0.5 (0.0; 2.5)
Respiratory tract infection viral	1	0.5 (0.0; 2.5)
Sinusitis	3	1.4 (0.3; 3.9)
Upper respiratory tract infection	3	1.4 (0.3; 3.9)
Urinary tract infection	2	0.9 (0.1; 3.2)
Viral infection	2	0.9 (0.1; 3.2)
Vulvovaginal mycotic infection	1	0.5 (0.0; 2.5)
Injury, poisoning and procedural complications		
Arthropod bite	2	0.9 (0.1; 3.2)

Injury	2	0.9 (0.1; 3.2)
Spinal compression fracture	1	0.5 (0.0; 2.5)
Investigations		
Blood cholesterol increased	1	0.5 (0.0; 2.5)
Metabolism and nutrition disorders		
Dehydration	1	0.5 (0.0; 2.5)
Musculoskeletal and connective tissue disorders		
Arthralgia	3	1.4 (0.3; 3.9)
Back pain	2	0.9 (0.1; 3.2)
Joint stiffness	1	0.5 (0.0; 2.5)
Musculoskeletal stiffness	1	0.5 (0.0; 2.5)
Myalgia	2	0.9 (0.1; 3.2)
Osteoarthritis	1	0.5 (0.0; 2.5)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Bronchial carcinoma	1	0.5 (0.0; 2.5)
Cervix carcinoma	1	0.5 (0.0; 2.5)
Prostate cancer	1	0.5 (0.0; 2.5)
Nervous system disorders		
Headache	3	1.4 (0.3; 3.9)
Migraine	1	0.5 (0.0; 2.5)
Taste disorder	1	0.5 (0.0; 2.5)
Psychiatric disorders		
Depression	1	0.5 (0.0; 2.5)
Insomnia	1	0.5 (0.0; 2.5)
Irritability	2	0.9 (0.1; 3.2)
Renal and urinary disorders		
Acute kidney injury	1	0.5 (0.0; 2.5)
Hydronephrosis	1	0.5 (0.0; 2.5)
Nephrolithiasis	1	0.5 (0.0; 2.5)
Respiratory, thoracic and mediastinal disorders		

Asthma	2	0.9 (0.1; 3.2)
Chronic obstructive pulmonary disease	2	0.9 (0.1; 3.2)
Cough	2	0.9 (0.1; 3.2)
Oropharyngeal pain	4	1.8 (0.5; 4.5)
Pulmonary hypertension	1	0.5 (0.0; 2.5)
Rhinorrhea	2	0.9 (0.1; 3.2)
Sneezing	1	0.5 (0.0; 2.5)
Wheezing	2	0.9 (0.1; 3.2)
Skin and subcutaneous tissue disorders		
Piloerection	1	0.5 (0.0; 2.5)
Urticaria	1	0.5 (0.0; 2.5)
Vascular disorders		
Hematoma	1	0.5 (0.0; 2.5)

MedDRA, Medical Dictionary for Regulatory Activities; OAD, obstructive airway disease; N, number of adults in the total vaccinated cohort; n/%, number/percentage of participants in a given category; CI, confidence interval.